Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Selection of Respiratory Syncytial Viruses Resistant to Palivizumab

15 Mar 2005

Abstract excerpt

Palivizumab (PZ) is the only monoclonal antibody currently available for use in humans against an infectious disease. PZ is administered prophylactically for respiratory syncytial virus (RSV) infections. RSV selected in cell culture for growth in the presence of PZ develops F gene mutations and can be resistant to PZ prophylaxis in cotton rats. Here, we evaluated the potential for PZ-resistant RSV mutants to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parvovirus B19 Infection Studies
Share to Respiratory viral infections research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15767398
DOI: 10.1128/jvi.79.7.3962-3968.2005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Selection of Respiratory Syncytial Viruses Resistant to PalivizumabPMID 15767398Read ↗

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.Semantic proximity Read ↗

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.Semantic proximity Read ↗

In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants.Semantic proximity Read ↗

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton RatsSemantic proximity Read ↗

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read ↗

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.Semantic proximity Read ↗

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read ↗

Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals modelsSemantic proximity Read ↗

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.Semantic proximity Read ↗

Lack of resistance development during brincidofovir therapy in animal models of orthopoxvirus infection.Semantic proximity Read ↗

Evolution of protection after maternal immunization for respiratory syncytial virus in cotton ratsSemantic proximity Read ↗

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in InfancySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.